Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees

Janine

Janine Bilsborough, Simi Valley, CA US

Patent application number	Description	Published
20100266600	METHODS OF USING IL-31 ANTAGONISTS IN DISEASES MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE T CELLS - The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.	10-21-2010
20110212093	METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS - The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.	09-01-2011
20110293514	METHODS OF USING IL-31 MONOCLONAL ANTIBODIES TO REDUCE INFLAMMATION - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.	12-01-2011

Janine Cherette, Middlesex, NJ US

Patent application number	Description	Published
20110311470	COMPOSITIONS FOR A POWDER HAVING AN AQUEOUS PHASE - In an embodiment of the present invention, there is provided a personal care composition having: a) at least one hydrophilic binder chosen from a sodium starch glycolate cross-linked with a phosphate ester group; b) at least one hydrophobic powder filler; and c) water, wherein the composition is in loose powder form. In another embodiment of the present invention, there is provided a method of making a personal care composition involving: a) forming a powder phase, comprising: i) at least one hydrophilic binder chosen from a sodium starch glycolate cross-linked with a phosphate ester group; and ii) at least one hydrophobic powder filler; b) providing an aqueous phase, comprising water; and c) adding the aqueous phase to the powder phase, wherein the personal care composition is in loose powder form.	12-22-2011

Janine Copp, Ruby Bay NZ

Patent application number	Description	Published
20100261218	METHODS FOR PRODUCING SECONDARY METABOLITES - The invention relates to methods for producing secondary metabolites using transformed	10-14-2010

Janine Fan, Hockessin, DE US

Patent application number	Description	Published
20100159516	ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of one or more alkylamine and optionally one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation.	06-24-2010
20100159517	ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution, under alkaline conditions, in the presence of one or more organo-mercaptan and optionally one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation.	06-24-2010
20100159518	ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of one of more sulfide (hydrosulfide) salt and optionally one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation.	06-24-2010
20100159519	ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of elemental sulfur and optionally one or more alkylamine and/or one or more additional nucleophile to fragment and extract lignin. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation.	06-24-2010
20100159520	ORGANIC SOLVENT PRETREATMENT OF BIOMASS TO ENHANCE ENZYMATIC SACCHARIFICATION - Biomass is pretreated using an organic solvent solution under alkaline conditions in the presence of ammonia and optionally an additional nucleophile to fragment and extract lignin without loss of hemicellulose. Pretreated biomass is further hydrolyzed with a saccharification enzyme consortium. Fermentable sugars released by saccharification may be utilized for the production of target chemicals by fermentation.	06-24-2010

Janine Lapage, Redondo Beach, CA US

Patent application number	Description	Published
20100173340	USE OF HEMATOPOIETIC GROWTH FACTOR INDUCIBLE NEUROKININ-1 (HGFIN) AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation. This method entails assaying a biological sample for HGFIN, wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of systemic inflammation. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.	07-08-2010
20110177613	Use of periostin as a novel biomarker - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.	07-21-2011

Janine Lin, Davis, CA US

Patent application number	Description	Published
20080274499	Polypeptides having alpha-glucosidase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	11-06-2008
20100120654	Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	05-13-2010
20100190680	Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	07-29-2010
20100192260	Polypeptides having alpha-glucosidase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	07-29-2010
20110053822	Polypeptides having lipase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	03-03-2011
20110171347	Polypeptides having Alpha-glucosidase activity and polynucleotides encoding same - The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	07-14-2011
20110224123	POLYPEPTIDES HAVING LIPASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	09-15-2011
20110239333	Polypeptides Having Xylanase Activity And Polynucleotides Thereof - The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.	09-29-2011

Janine Löhr, Berlin DE

Patent application number	Description	Published
20100303803	CATENATE FOR IMMUNOSTIMULATION - The invention relates to a multimeric, non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a production method therefor, and to a vaccine containing said multimeric, non-coding nucleic acid molecule. Said multimeric, non-coding nucleic acid molecules can be non-coding nucleic acid molecules that consist of at least two of said molecules (dimer) or assemblies of several non-coding nucleic acid molecules.	12-02-2010

Janine Penaflor, Nipomo, CA US

Patent application number	Description	Published
20090179414	Protective book cover for a paperback type book - A protective covering for a paperback book provides a generally rectangular, foldable, protective sheet divided into a plurality of linearly adjoining panels. These panels include a front flap panel, a front cover panel, a spine panel, a rear cover panel, and a rear flap panel. Preferably each one of the adjacent panels is separated by at least one scoring line, allowing the panels to be easily and selectively folded around the outside of a paperback book. Adhesive portions are engaged with each one of the flap panels as well as the spine panel, each adhesive portion preferably providing a low-tack, reusable adhesive that enabling the protective covering to be easily attached and removed without leaving marks or residue on the book.	07-16-2009

Janine Schwiertz, Mulheim DE

Patent application number	Description	Published
20110257586	CALCIUMPHOSPHATE-BASED NANOPARTICLES AS CARRIER-SYSTEMS FOR PHOTODYNAMIC THERAPY - The present invention provides pharmaceutical photosensitizer-loaded nanoparticle formulations and their methods of preparation for photodynamic therapy, comprising a hydrophobic or hydrophilic photosensitizer, nanoparticulate calcium phosphate and in certain cases auxiliary reagents such as stabilizers. The calcium phosphate-based nanoparticle formulations of the present invention provide excellent storage stability and therapeutically effective amounts of photosensitizer for intravenous or topical administration. In a preferred embodiment, tetrapyrrole derivatives such as porphyrins, chlorins and bacteriochlorins, are the preferred hydrophobic photosensitizers to be formulated in calcium phosphate nanoparticle formulations for photodynamic tumor therapy. Additionally, 5,10,15,20-tetrakis(4-phosphonooxyphenyl)porphine (pTPPP) is a preferred hydrophilic photosensitizer for photodynamic tumor therapy. In another preferred embodiment, hydrophilic cationic and anionic photosensitizers, especially those of the phenazinium, phenothiazinium and xanthenes series have been found to inactive pathogen bacteria and are the preferred photosensitizers to be formulated in calcium phosphate nanoparticle formulations for antibacterial photodynamic therapy. In another embodiment, photosensitizing nanoparticle formulations are useful to locate cells, tissues or bacteria by using fluorescence imaging methods.	10-20-2011

Janine Senz, Vancouver CA

Patent application number	Description	Published
20110195070	DETECTION OF GRANULOSA-CELL TUMORS - A method of detecting a granulosa-cell tumor is described herein. The method involves detecting a mutation in a sample derived from a subject, indicative of substitution of tryptophan in place of cysteine at amino acid position 134 of FOXL2 protein. The mutation may be detected as a DNA mutation 402C>G in the FOXL2 gene. Methods for screening for a granulosa-cell tumor from a blood-based assay are provided, as well as methods for making a determination that an ovarian tumor is not a granulosa-cell tumor. Kits for granulosa-cell tumors are described, and a method of treating a granulosa-cell tumor are also described.	08-11-2011

Janine Shulok, Newton, MA US

Patent application number	Description	Published
20120023600	COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES OF DICKKOPF-1 - Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition.	01-26-2012

Janine Tadje, Magdeburg DE

Patent application number	Description	Published
20110117069	METHOD FOR ACTIVATING REGULATORY T-CELLS - The invention relates to a method for activating regulatory t-cells (Treg-cells) of the human or animal body, comprising a step of bringing into contact the regulatory t-cells (Treg-cells) in a suitable liquid medium with one or a plurality of inhibitors of alanyl-amino peptidase (amino peptidase N; APN) and/or with one or a plurality of inhibitors of peptidases with the same substrate specificity to induce a suppressive effect of the regulatory t-cells (Treg-cells).	05-19-2011